RPG Life Sciences Reports 8% Revenue Rise, Announces 300% Dividend
Verified article - details checked for accuracy.
Data Extracted via Frism DocuLens
RPG Life Sciences Limited posted 8% revenue growth but saw profit plunge, while cash surged and a 300% dividend was announced.
- Revenue rose to Rs 70,752 lakhs (+8% YoY); net profit fell to Rs 11,517 lakhs (EPS Rs 69.64) from Rs 18,324 lakhs, cutting the profit margin to ~16%.
- Cash & cash equivalents jumped to Rs 15,046 lakhs (from Rs 2,870 lakhs) driven by a Rs 3,137 lakhs insurance settlement; operating cash flow was Rs 5,650 lakhs.
- Board approved a final dividend of Rs 24 per share (300% of face value) and added Dr. Pratit Samdani as an additional non‑executive independent director.
- Long‑term borrowings increased by Rs 2,000 lakhs, raising total liabilities to Rs 18,781 lakhs and debt‑to‑equity to ~0.31; one‑off charges include a Rs 916 lakhs intangible write‑off and a Rs 1,169 lakhs labour‑code provision.
- Approval was given to transfer the API division to wholly‑owned subsidiary RPG Active Pharma Ltd., pending regulatory consents, to sharpen focus on higher‑margin segments.
Complete ArticleExclusive Frism Intelligence Report
Frism is a financial information and news discovery platform. We provide factual summaries and data correlations for educational and informational purposes only. Frism does not provide investment advice, buy/sell recommendations, or directional market outlooks. Users should consult a qualified financial advisor before making any investment decisions.
Proudly crafted in India 🇮🇳
Frism Computing (OPC) Private Limited
#74, 15TH CROSS, JP Nagar III Phase, Bangalore South, Bangalore 560078, Karnataka